FDA Authorizes Roche and Eli Lilly Blood Test for Alzheimer’s Detection
The U.S. Food and Drug Administration (FDA) authorized a new blood test developed by Roche and Eli Lilly designed to help identify signs of Alzheimer’s disease in patients aged 55 and older with cognitive impairment, Roche announced. The regulatory milestone broadens diagnostic options for clinicians evaluating amyloid pathology, a brain alteration associated with the most common form of dementia.
- The FDA authorized the Elecsys Phospho-Tau (217P) plasma test to evaluate the probability of amyloid pathology in individuals aged 55 and older experiencing cognitive decline.
- The assay is designed to run on existing laboratory infrastructure, utilizing Roche’s installed analyzers across the United States without requiring specialized new equipment.
- Major diagnostic providers including Labcorp and Quest Diagnostics have announced plans to incorporate the test into their service networks, widening accessibility.
The newly cleared assay, known commercially as the Elecsys pTau217 blood test, measures specific biomarkers in plasma to help physicians determine whether a patient likely harbors brain changes linked to Alzheimer’s disease. According to Roche, the test integrates directly into standard laboratory workflows. This operational efficiency bypasses the necessity for facilities to acquire dedicated hardware, distinguishing it from traditional diagnostic pathways that rely on specialized imaging or cerebrospinal fluid extraction.
Historically, confirming amyloid pathology required invasive or expensive procedures such as positron emission tomography (PET) scans or lumbar punctures. While those methods remain standard clinical tools, blood-based biomarkers measuring phosphorylated tau 217 (p-tau217) “predict with great accuracy” the accumulation of beta-amiloide plaques, as noted by Rachel Buckley, associate professor of neurology at Harvard Medical School. These protein aggregates can accumulate in the brain decades before clinical memory loss manifests, disrupting neuronal communication and triggering inflammation.
Despite the analytical validity of the plasma assay, regulatory approval comes with strict clinical caveats. Roche explicitly notes that the test is not designed to serve as a standalone diagnostic tool. Results must be interpreted in conjunction with comprehensive clinical evaluations and patient histories. Dr. Richard Isaacson, director of research at the Institute for Neurodegenerative Diseases of Florida, emphasized in correspondence with media outlets that individual Alzheimer’s blood tests present distinct clinical challenges. Comparing the diagnostic approach to routine cardiovascular screening, Isaacson pointed out that physicians evaluate patient risk using comprehensive clinical panels rather than isolated biomarkers to minimize false-positive risks.
The regulatory clearance arrives amid heightened competition among pharmaceutical firms and diagnostic developers racing to meet surging demand for early detection tools. In 2025, the FDA authorized the Lumipulse test from Fujirebio as the first plasma-based screening aid for Alzheimer’s disease. Roche also secured authorization last year for its Elecsys pTau181 assay, which targets a different protein variant. Additionally, C2N Diagnostics received agency clearance for its Precivity AD2 test.
Epidemiological urgency underpins these diagnostic advancements. The Centers for Disease Control and Prevention (CDC) estimates that 6.7 million older adults live with Alzheimer’s disease in the United States, accounting for 60% to 80% of all dementia cases. Federal projections indicate this patient population will double by the year 2060. Research from Alzheimer’s Disease International in 2021 suggests that while roughly 55 million individuals worldwide suffer from dementia, approximately 75% of cases remain undiagnosed.
As diagnostic laboratories adopt these minimally invasive screening tools, primary care physicians and specialists must coordinate closely to interpret biomarker data accurately.
Looking ahead, the integration of plasma biomarker testing into routine clinical practice will depend heavily on physician education and the establishment of standardized multi-marker panels. As diagnostic networks expand, patients seeking timely evaluations should consult qualified [Neurology Specialists] to determine appropriate diagnostic pathways.
*Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.*